RedHill Biopharma (RDHL) Consolidated Net Income (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Consolidated Net Income data on file, last reported at $58.9 million in Q2 2023.

• On a quarterly basis, Consolidated Net Income rose 791.8% year-over-year to $58.9 million in Q2 2023; TTM through Dec 2024 was $58.9 million, a 418.17% increase from a year earlier, with the FY2025 full-year figure at $7.7 million, up 188.68% from the prior year.
• Consolidated Net Income for Q2 2023 stood at $58.9 million, up from -$7.9 million in the prior quarter.
• Over the last five years, Consolidated Net Income for RDHL reached as high as $58.9 million in Q2 2023 and fell as low as -$134.0 million in Q4 2021.
• Historically, Consolidated Net Income has averaged -$271388.9 across 5 years, with a median of $11.1 million in 2019.
• Across the five-year window, Consolidated Net Income sank 714.12% in 2021 and surged 791.8% in 2023, its largest moves.
• Year by year, Consolidated Net Income stood at $11.8 million in 2019, then soared by 84.27% to $21.8 million in 2020, then sank by 714.12% to -$134.0 million in 2021, then surged by 48.1% to -$69.5 million in 2022, then surged by 184.75% to $58.9 million in 2023.
• Per Business Quant data, the three most recent Consolidated Net Income figures were $58.9 million in Q2 2023, -$7.9 million in Q1 2023, and -$69.5 million in Q4 2022.